Opdivo & Cabometyx Show 4-Year Benefits in RCC Trial
Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) has shown continued benefits in the first-line treatment of advanced renal cell...
KoNECT And Its Remarkable Role in Korean Clinical Trials
In today’s interview, we’re speaking with Dr. In-seok Park, Ph.D., the esteemed President of KoNECT. Dr. Park, who assumed...
FDA Needs To Release ClinicalTrials.gov Guidance Now
The 2024 Clinical Trials Transformation Initiative (CTTI) report, drawing on a broad spectrum of responses from diverse stakeholders in...
Arcus & Gilead: Quemliclustat Regimens Show Hope in Pancreatic Cancer
Arcus Biosciences, Inc. announced promising overall survival data from the ARC-8 Phase 1b trial, co-developed with Gilead Sciences. The...
Latest Clinical Trial Tech Emerges: A Medidata NEXT Insight
At the 2023 Medidata NEXT conference, prominent figures like Michelle Hartman from South Broward Research, Adam Kinsey from Merck,...
Takeda’s HYQVIA Wins FDA Approval for CIDP Therapy
Takeda has announced that the FDA has approved HYQVIA® for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as...
Dubai’s Arab Health: Leading New Medical Advances
Join us at the Arab Health 2024 conference, set in the vibrant city of Dubai, from January 29 to...
FDA Nods Merck’s Keytruda for Stage III-IVA Cervical Cancer
Merck announced that the FDA has approved KEYTRUDA, their anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for treating patients...
Innovative DCT Leap: Bayer’s New OCEANIC Study
The Vanguard of Decentralized Clinical Trials: Bayer’s OCEANIC Study The Medidata NEXT conference spotlighted the groundbreaking OCEANIC study by...
Revolutionary Digital Twins: The Future of Clinical Trials
In this interview with Gian Carlo (GC) Ochoa, a leading figure in digital twins technology for clinical trials, we...